CytoDyn (CYDY) Total Liabilities (2011 - 2026)
CytoDyn's (CYDY) quarterly Total Liabilities came in at $122.8 million in Q1 2026, up 7.54% YoY from $114.2 million in Q1 2025, and down 4.58% on a QoQ basis from $128.7 million in Q4 2025.
CytoDyn (CYDY) Total Liabilities (2011 - 2026) Analysis & Trends
CytoDyn (CYDY) has 16 years of Total Liabilities data on file, last reported at $122.8 million in Q1 2026.
- Quarterly Total Liabilities rose 7.54% year-over-year to $122.8 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $122.8 million (up 7.54% YoY) and the FY2025 annual result came in at $114.1 million, down 10.79% from the prior year.
- Total Liabilities declined to $122.8 million in Q1 2026, from $128.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $129.7 million in Q1 2024 to a low of $113.0 million in Q3 2025.
- A 5-year average of $121.1 million and a median of $122.7 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities dropped 19.28% — and 2025, when it gained 12.62%.
- Tracing CYDY's Total Liabilities over 5 years: stood at $123.0 million in 2022, then gained by 0.47% to $123.6 million in 2023, then declined by 7.57% to $114.3 million in 2024, then rose by 12.62% to $128.7 million in 2025, then slipped by 4.58% to $122.8 million in 2026.
- The last three Total Liabilities figures came in at $122.8 million (Q1 2026), $128.7 million (Q4 2025), and $113.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | 122.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 122.78 Mn |
| Nov 30, 2025 | 128.68 Mn |
| Aug 31, 2025 | 112.99 Mn |
| May 31, 2025 | 114.09 Mn |
| Feb 28, 2025 | 114.17 Mn |
| Nov 30, 2024 | 114.27 Mn |
| Aug 31, 2024 | 113.23 Mn |
| May 31, 2024 | 127.89 Mn |
| Feb 29, 2024 | 129.65 Mn |
| Nov 30, 2023 | 123.62 Mn |
| Aug 31, 2023 | 129.30 Mn |
| May 31, 2023 | 120.79 Mn |
| Feb 28, 2023 | 121.65 Mn |
| Nov 30, 2022 | 123.04 Mn |
| Aug 31, 2022 | 122.71 Mn |
| May 31, 2022 | 123.58 Mn |
| Feb 28, 2022 | 116.54 Mn |
| Nov 30, 2021 | 116.40 Mn |
| Aug 31, 2021 | 130.16 Mn |
| May 31, 2021 | 153.10 Mn |